Barclays analyst Douglas Tsao says that while he'd probably stop short of calling it "mission impossible," he sees "significant challenges" in the development of a biosimilar to Allergan's (AGN) Botox.Those are the verbatim phrases used by AGN's CCO, Bill Meury, on a recent webcast. What does that tell you?